echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Phase 2/3 clinical trials of Moderna's COVID-19 vaccine for children under 6 years old meet primary endpoint

    Phase 2/3 clinical trials of Moderna's COVID-19 vaccine for children under 6 years old meet primary endpoint

    • Last Update: 2022-04-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Compilenewborn

    Recently, Moderna announced positive interim data from the Phase 2/3 KidCOVE study of its COVID-19 vaccine (mRNA-1273)
    .
    The study was conducted in children 6 months to 2 years old and 2 years old to under 6 years old, and the interim analysis showed that the 25µg two-dose immunization schedule showed strong neutralizing antibody responses and good safety in both age groups.
    sex

    .

    Based on these data, Moderna will submit a license application in the coming weeks to the U.
    S.
    FDA, European Medicines Agency and other global regulators to administer the mRNA-1273 vaccine 25µg two-dose immunization schedule to children 6 months to under 6 years of age

    .

    KidCOVE is a randomized, observer-blind, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of two doses of mRNA-1273, 28 days apart, in a population of healthy children
    .
    The study population was divided into 3 age groups (6 to <12 years, 2 to <6 years, and 6 months to <2 years)

    .
    In this study, efficacy can be assessed if a sufficient number of cases are accumulated

    .
    Overall, Moderna has enrolled approximately 11,700 pediatric participants in the U.
    S.
    and Canada, including approximately 4,200 children 2 to under 6 years of age and approximately 2,500 children 6 months to under 2 years of age

    .

    Data are reported for the age groups 6 months to under 2 years and 2 years to under 6 years
    .
    In both age groups, the tolerability profile of the mRNA-1273 vaccine was largely consistent with that observed in children aged 6 to under 12 years, adolescents aged 12 to 17 years, and adults

    .
    Most adverse events were mild or moderate and were reported more frequently after the second vaccination

    .
    The rate of fever above 38°C in the vaccinated population was consistent with other commonly used and recommended pediatric vaccines, at 17.
    0% and 14.
    6% in the 6 months to under 2 and 2 to under 6 age groups, respectively, and in the 6-year 23.
    9% in the age group below 12 years (2-dose schedule of 50 µg for this age group)

    .
    Fever above 40°C occurred in only a few children (0.
    2% in each age group)

    .
    Neither age group met study suspension rules and no new safety concerns were identified

    .
    No deaths, myocarditis or pericarditis, and multisystem inflammatory syndrome in children (MIS-C) were reported

    .

    In these 2 age groups, the immunogenicity of the two-dose 25-µg immunization was similar to that of the 100-µg two-dose immunization in adults 18 to 25 years old, meeting noninferiority criteria and immune bridging, indicating that mRNA-1273 was 18-25 The benefits for adults as young as 6 months are also available to children and infants as young as 6 months old
    .
    The SARS-Cov-2 neutralizing antibody geometric mean ratio (GMR) results were compared between the responses in the 6 months to <2 years old age group and the 2 to <6 years old age group with the responses of young adults in the phase 3 COVE study.
    is 1.
    3 (95%Cl: 1.
    1, 1.
    5), 1.
    0 (95% Cl: 0.
    9, 1.
    2)

    .
    This also heralds the protective effect of mRNA-1273 against COVID-19 and severe COVID-19 disease, with benefit populations as young as 6 months old

    .

    During the KidCOVE study in these young populations, the Omicron variant of SARS-CoV-2 was circulating in the United States
    .
    The secondary endpoint of vaccine efficacy demonstrated statistical significance, but, as expected, was less effective in preventing COVID-19 infection during the Omicron epidemic, consistent with observational data in adults

    .
    Using the Phase 3 COVE study COVID-19 definitions, vaccine efficacy was 43.
    7% in the 6 months to 2 year age group and 37.
    5% in the 2 to under 6 year age group

    .
    In this case, statistical significance was defined as the lower bound of the 95% confidence interval greater than 0

    .
    Most cases were mild, with no severe COVID-19 disease observed in either age group

    .
    The efficacy of mRNA-1273 to prevent these endpoints could not be assessed as there were no serious illnesses, hospitalizations, or deaths in the study

    .

    Similar to adults, Moderna is preparing to evaluate the potential of the mRNA-1273 vaccine booster in all pediatric populations, including 6 months to <6 years, 6 to <12 years, and adolescents
    .
    Currently, the company is evaluating a booster shot of mRNA-1273 and a bivalent vaccine candidate (mRNA-1273.
    214), which is a complex of the Omicron-specific booster vaccine candidate with mRNA-1273

    .

    Reference source: Moderna Announces its COVID-19 Vaccine Phase 2/3 Study in Children 6 Months to Under 6 Years Has Successfully Met Its Primary Endpoint

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.